

CLAIMS

- 1) Use of HMG box binding molecules for the preparation of therapeutic agents for the treatment of vascular diseases related to endothelial and smooth muscle cells proliferation.
- 5 2) Use of HMG box binding molecules for the preparation of therapeutic agents for the treatment of vascular diseases related, to endothelial and smooth muscle cells proliferation due to atherosclerosis and/or restenosis after blood vessels damage.
- 10 3) Use of HMG box binding molecules for the preparation of therapeutic agents for the treatment of vascular diseases related to endothelial and smooth muscle cells proliferation and due to atherosclerosis and/or restenosis after blood vessels damage, including
15 those events that occur after coronary and/or carotid angioplasty, with or without stent positioning, angiographic surgery, and surgery using catheters.
- 4) Use of HMG box binding molecules according to claim 1 wherein said molecules belong to the group
20 comprising antibodies or antibodies fragments, inhibitors and four-way DNA.
- 5) Use of antagonist molecules having sequence homology with HMG box and being able to bind the functional HMG box binding domain of the receptor for
25 the preparation of therapeutic agents for the treatment of vascular diseases related to smooth muscle and endothelial cells proliferation.
- 6) Use of antagonist molecules having sequence homology with HMG box and being able to bind the functional HMG box binding domain of the receptor for
30 the preparation of therapeutic agents for the treatment

of vascular diseases related to smooth muscle and endothelial cells proliferation due to atherosclerosis and/or restenosis after blood vessels damage.

- 7) Use of antagonist molecules having sequence
- 5 homology with HMG box and being able to bind the functional HMG box binding domain of the receptor for the preparation of therapeutic agents for the treatment of vascular diseases related to endothelial and smooth muscle cells proliferation and due to atherosclerosis
- 10 and/or restenosis after blood vessels damage, including those events that occur after coronary and/or carotid angioplasty, with or without stent positioning, angiographic surgery, and surgery using catheters.

- 8) Therapeutic agent for the treatment of vascular
- 15 diseases related to smooth muscle and endothelial cells proliferation characterised in that it comprises a therapeutic active amount of HMG box binding molecules.

- 9) Therapeutic agent for the treatment of vascular diseases related to smooth muscle and endothelial cells
- 20 proliferation according to claim 8 wherein said molecules belong to the group comprising antibodies or antibodies fragments, inhibitors and four-way DNA and not sRAGE.

- 10) Therapeutic agent for the treatment of
- 25 vascular diseases related to smooth muscle and endothelial cells proliferation characterised in that it comprises a therapeutic active amount of antagonist molecules having sequence homology with HMG box and being able to bind the functional HMG box binding
- 30 domain of the receptor.

11) Therapeutic agent according to claims from 8 to 10 characterised in that it is released by catheters, surgical instruments implants or stents.